Jos de Man

Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use

Joost C.M. Uitdehaag, Jeroen A.D.M. de Roos, Antoon M. van Doornmalen et al. · PLoS ONE · 2014 · 99 citations · Full text

Kinase Inhibitor Drugs, Tumor Biology, Clinical Use +16

TTK Inhibitors as a Targeted Therapy for <i>CTNNB1</i> ( <b>β</b> -catenin) Mutant Cancers

Guido J.R. Zaman, Jeroen A.D.M. de Roos, Marion A.A. Libouban et al. · Molecular Cancer Therapeutics · 2017 · 63 citations · Full text

Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity

Joost C.M. Uitdehaag, Jos de Man, Nicole Willemsen‐Seegers et al. · Journal of Molecular Biology · 2017 · 62 citations

Drug Target, Signal Transduction, Signaling Pathway +10

Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance

Nicole Willemsen‐Seegers, Joost C.M. Uitdehaag, Martine B.W. Prinsen et al. · Journal of Molecular Biology · 2016 · 49 citations

Molecular Docking, Medicinal Chemistry, Drug Target +11

Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158

Yvonne Grobben, Joost C.M. Uitdehaag, Nicole Willemsen‐Seegers et al. · Journal of Structural Biology X · 2019 · 40 citations · Full text